Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autoimmune Diseases Clear all
Terminated Not applicable Interventional Results available

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

NCT00870818
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Diagnostic Test · Behavioral
Lead sponsor
MacroGenics
Industry
Eligibility
10 Years to 37 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis

NCT04496804
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Behavioral Intervention for Physical Activity in MS (BIPAMS), Wellness for MS (WellMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Jun 10, 2026, 5:43 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Acupressure for Fatigue in Systemic Lupus Erythematosus

NCT03200548
View directory record Official record
Conditions
Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life, Sleep
Interventions
Relaxing acupressure plus usual care, Usual care, Stimulating acupressure plus usual care, Sham acupressure plus usual care
Behavioral
Lead sponsor
Suzanna Zick
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jun 10, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 20 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

NCT06117020
View directory record Official record
Conditions
Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis, Stroke, Hereditary Spastic Paraplegia, Dystonia, Spinal Cord Injuries
Interventions
MTR-601
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 5:43 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jun 10, 2026, 5:43 PM EDT
Terminated Phase 3 Interventional Results available

Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients

NCT01784523
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects

NCT01357759
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MORAb-022
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Jacksonville, Florida • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2015 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus

NCT04201496
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks, No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks, No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Combination Product · Device
Lead sponsor
Ananda Basu, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Jun 10, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

NCT04929379
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus

NCT01438489
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
30
States / cities
Birmingham, Alabama • La Jolla, California • La Palma, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Jun 10, 2026, 5:43 PM EDT
Completed No phase listed Observational

A Survey To Elicit The Relationship Between Literacy And Glycemic Control In Pediatric Diabetes

NCT00717223
View directory record Official record
Conditions
Diabetes, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Jun 10, 2026, 5:43 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
IMU-838 tablets, Placebo matching IMU-838 tablets
Drug
Lead sponsor
Immunic AG
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
2
States / cities
Altamonte Springs, Florida • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis

NCT04678115
View directory record Official record
Conditions
Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury, Chronic Progressive External Ophthalmoplegia
Interventions
Magnetic Levator Prosthesis (MLP), Kinesiotape Frontalis Sling (KTFS)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Dalfampridine on Cognition in Multiple Sclerosis

NCT02006160
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dalfampridine, placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

NCT00904826
View directory record Official record
Conditions
Neuromyelitis Optica, Devic's Disease
Interventions
Eculizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Jun 10, 2026, 5:43 PM EDT
Completed No phase listed Observational

A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)

NCT00443443
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
192
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 170 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2015 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

NCT03378635
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Type 1
Interventions
Dasiglucagon, GlucaGen, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

NCT01500278
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX)
Biological · Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Jun 10, 2026, 5:43 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia

NCT06651515
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Allogeneic Pancreatic Endocrine Cell Clusters
Biological
Lead sponsor
Seraxis
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jun 10, 2026, 5:43 PM EDT
Terminated Not applicable Interventional

Resistance Exercise in Rheumatic Disease

NCT01599260
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Vasculitis
Interventions
Resistance Exercise
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jun 10, 2026, 5:43 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

NCT02780674
View directory record Official record
Conditions
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Interventions
MEDI7734, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jun 10, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System

NCT01271023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control-to-Range Automated Insulin Management System
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jun 10, 2026, 5:43 PM EDT